Ocumension Therapeutics (FRA:5DG)

Market Cap	716.70M
Revenue (ttm)	64.63M
Net Income (ttm)	-29.63M
Shares Out	n/a
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	1
Open	0.8050
Previous Close	0.7900
Day's Range	0.8050 - 0.8050
52-Week Range	0.4400 - 1.3500
Beta	n/a
RSI	49.79
Earnings Date	Mar 27, 2026

About Ocumension Therapeutics

Ocumension Therapeutics, together with its subsidiaries, operates as an ophthalmic pharmaceutical platform company in the People's Republic of China. It discovers, develops, and commercializes therapies for ophthalmic patients. Its portfolio includes products and drugs for the treatment of chronic non-infectious uveitis, infective and allergic conjunctivitis, diabetic macular edema, dry eye, glaucoma and ocular hypertension, postoperative inflammation, choroidal neovascularization, bacterial conjunctivitis, retinitis pigmentosa, age-related mac...

• Industry: Pharmaceutical Preparations
• Founded: 2017
• Employees: 489
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 5DG

Financial Performance

In 2024, Ocumension Therapeutics's revenue was 417.31 million, an increase of 69.38% compared to the previous year's 246.37 million. Losses were -268.27 million, -29.36% less than in 2023.

Financial numbers in CNY